Similar articles for PMID: 29735826

Year	Number of Results
1994	1
1996	1
1999	2
2000	1
2001	4
2002	4
2003	4
2004	2
2005	5
2006	1
2007	4
2008	4
2009	8
2010	7
2011	3
2012	7
2013	6
2014	4
2015	11
2016	5
2017	6
2018	6
2019	8
2020	6
2021	10
2022	21
2023	10
2024	0

1

Cytomegalovirus reactivation and disease amongst patients with allogeneic haematopoietic stem cell transplantation in Eastern India: Epidemiology, outcome and healthcare cost.

Kumar M, Roychowdhury M, Kumar J, Harishankar A, Sinha S, Bhave SJ, Chakrapani A, Radhakrishnan V, Nair R, Bhattacharya S, Chandy M. Kumar M, et al. Indian J Med Microbiol. 2018 Jan-Mar;36(1):49-53. doi: 10.4103/ijmm.IJMM_17_269. Indian J Med Microbiol. 2018. PMID: 29735826 Free article.

2

Cytomegalovirus reactivation following hematopoietic stem cell transplantation.

Sharma SK, Kumar S, Agrawal N, Singh L, Mukherjee A, Seth T, Mishra P, Mathur S, Dar L, Mahapatra M. Sharma SK, et al. J Infect Dev Ctries. 2013 Dec 15;7(12):1003-7. doi: 10.3855/jidc.2947. J Infect Dev Ctries. 2013. PMID: 24334950 Free article.

3

Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.

Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C. Serio B, et al. Infez Med. 2012;20 Suppl 2:26-34. Infez Med. 2012. PMID: 23042003 Free article.

4

Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.

Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M. Busca A, et al. Transpl Infect Dis. 2007 Jun;9(2):102-7. doi: 10.1111/j.1399-3062.2006.00183.x. Transpl Infect Dis. 2007. PMID: 17461994

5

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K. George B, et al. Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11. Transpl Infect Dis. 2010. PMID: 20487414

6

Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.

Jaing TH, Chang TY, Chen SH, Wen YC, Yu TJ, Lee CF, Yang CP, Tsay PK. Jaing TH, et al. Medicine (Baltimore). 2019 Jan;98(4):e14172. doi: 10.1097/MD.0000000000014172. Medicine (Baltimore). 2019. PMID: 30681583 Free PMC article.

7

Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.

Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W. Boeckh M, et al. Ann Intern Med. 2015 Jan 6;162(1):1-10. doi: 10.7326/M13-2729. Ann Intern Med. 2015. PMID: 25560711 Free PMC article. Clinical Trial.

8

Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.

Yoon JH, Lee S, Kim HJ, Jeon YW, Lee SE, Cho BS, Lee DG, Eom KS, Kim YJ, Min CK, Cho SG, Min WS, Lee JW. Yoon JH, et al. Oncotarget. 2016 Mar 29;7(13):17230-41. doi: 10.18632/oncotarget.7347. Oncotarget. 2016. PMID: 26883100 Free PMC article.

9

Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.

Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA. Almyroudis NG, et al. Transpl Infect Dis. 2007 Dec;9(4):286-94. doi: 10.1111/j.1399-3062.2007.00235.x. Epub 2007 May 19. Transpl Infect Dis. 2007. PMID: 17511819

10

Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.

Dwabe S, Hsiao M, Ali A, Rodman J, Savitala-Damerla L, Nazaretyan S, Kimberly Schiff NP, Tam E, Ladha A, Woan K, Chaudhary P, Yaghmour G. Dwabe S, et al. Transpl Immunol. 2023 Feb;76:101769. doi: 10.1016/j.trim.2022.101769. Epub 2022 Dec 2. Transpl Immunol. 2023. PMID: 36464218

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

130 results

Results by year